Abbott Laboratories Stock (NYSE:ABT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$95.84

52W Range

$81.97 - $137.49

50D Avg

$89.15

200D Avg

$111.25

Market Cap

$165.79B

Avg Vol (3M)

$13.33M

Beta

0.61

Div Yield

$2.44 (2.56%)

ABT Company Profile


Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

114,000

IPO Date

Mar 17, 1980

Website

ABT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Nutritional Products$8.45B$8.41B$8.15B
Established Pharmaceutical Products$5.54B$5.19B$5.07B
Diagnostic Products$8.94B$9.34B$9.99B
Medical Devices$21.39B$18.99B$16.89B

Fiscal year ends in Dec 25 | Currency in USD

ABT Financial Summary


Dec 25Dec 24Dec 23
Revenue$44.33B$41.95B$40.11B
Operating Income$8.05B$6.83B$6.43B
Net Income$6.52B$13.40B$5.72B
EBITDA$11.33B$10.83B$10.61B
Basic EPS$3.74$7.67$3.30
Diluted EPS$3.72$7.64$3.27

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26Apr 16, 26 | 9:00 AM
Q4 25Jan 22, 26 | 9:00 AM
Q3 25Oct 15, 25 | 9:00 AM

Peer Comparison


TickerCompany
MDTMedtronic plc
NVSNovartis AG
NVONovo Nordisk A/S
BSXBoston Scientific Corporation
ISRGIntuitive Surgical, Inc.
GILDGilead Sciences, Inc.
SYKStryker Corporation
TMOThermo Fisher Scientific Inc.
UNHUnitedHealth Group Incorporated
MRKMerck & Co., Inc.